2024-03-25
1. Summary of the week
From March 15 to 21, a total of 9 licensing and cooperation agreements were executed worldwide. Within the China Biotech Industry, there were 2 out-licensing deals and 1 in-licensing deal. Bio-Thera Solutions and SteinCaressigned an out-licensing agreement for 2 biosimilar assets, while TaiMedBiologics and AcedrA BioPharmaceuticals inked an out-licensing pact for ibalizumab. Additionally, Bayer and Joincare Pharmaceutical entered into an in-licensing deal for small molecule inhibitors.
On a global scale, 6 licensing and cooperation agreements were sealed during this period. Notably, the licensing agreement between Fennec Pharmaceuticals and Norgine stood out, featuring an upfront payment of $43 million and a total deal value amounting to $270 million.
3月15日-21日，全球市场共达成9起医药资产授权合作交易。中国市场上，共有2起资产出海交易和1起资产引进交易。百奥泰将2个生物类似药资产的巴西和拉丁美洲权益转让给SteinCares；中裕新药将抗艾滋病药物Ibalizumab 的中东和北非权益转让给Acedra。健康元药业引进拜耳一款用于呼吸系统疾病的小分子抑制剂。
国际市场上，共有6起资产授权合作交易。最大的一起来自Fennec与Norgine达成的资产授权交易，首付43M美元，交易总价值270M美元。
2. Licensing Deals
2a. China section
2b. Global section
3.M&A Deals
4. Top Deals of the year 2024
5. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
ACCESS CHINA
Event Name: ACCESS CHINA Partnering Forum @BIO
Date & Time: June 3-20, 2024
Venue: San Diego & Online
Content: Keynote Speeches, Panel Discussion, Virtual Roadshows, Dinner Reception, 1X1 meetings
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
Registration Link: https://jinshuju.net/f/AqkB9m
BioToChina.org 